Sernova (TSE:SVA) PT Lowered to C$2.50 at Ventum Financial

Sernova (TSE:SVA) had its target price cut by Ventum Financial from C$3.00 to C$2.50 in a research report released on Friday morning, BayStreet.CA reports. They currently have a buy rating on the stock.

Separately, Leede Financial cut their price objective on Sernova from C$3.00 to C$1.50 and set a speculative buy rating on the stock in a report on Friday.

Sernova Price Performance

TSE SVA opened at C$0.26 on Friday. The stock’s 50-day moving average price is C$0.27 and its two-hundred day moving average price is C$0.37. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The company has a market cap of C$82.72 million, a PE ratio of -1.96 and a beta of 1.38. Sernova has a 1 year low of C$0.20 and a 1 year high of C$0.83.

Sernova (TSE:SVA) last posted its quarterly earnings data on Friday, June 14th. The company reported C($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of C($0.03). On average, analysts predict that Sernova will post -0.08 EPS for the current year.

Insider Activity

In other news, Director Steven Sangha sold 930,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total value of C$223,200.00. Insiders have acquired 359,600 shares of company stock worth $92,771 in the last 90 days. Company insiders own 12.98% of the company’s stock.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.